113 related articles for article (PubMed ID: 38091844)
41. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
42. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
43. The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma.
Roh J; Pak HK; Jeong S; Hwang S; Kim DE; Choi HS; Kim SJ; Kim H; Cho H; Park JS; Jeong SH; Choi YS; Han JH; Yoon DH; Park CS
Biochem Biophys Res Commun; 2023 Sep; 673():36-43. PubMed ID: 37356143
[TBL] [Abstract][Full Text] [Related]
44. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
45. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
[TBL] [Abstract][Full Text] [Related]
46. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
Dlouhy I; Karube K; Enjuanes A; Salaverria I; Nadeu F; Ramis-Zaldivar JE; Valero JG; Rivas-Delgado A; Magnano L; Martin-García D; Pérez-Galán P; Clot G; Rovira J; Jares P; Balagué O; Giné E; Mozas P; Briones J; Sancho JM; Salar A; Mercadal S; Alcoceba M; Valera A; Campo E; López-Guillermo A
Br J Haematol; 2022 Feb; 196(3):589-598. PubMed ID: 34632572
[TBL] [Abstract][Full Text] [Related]
47. MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy.
Zhou M; Wang J; Ouyang J; Xu JY; Chen B; Zhang QG; Zhou RF; Yang YG; Shao XY; Xu Y; Chen YM; Fan XS; Wu HY
Tumour Biol; 2014 Jul; 35(7):6757-62. PubMed ID: 24719189
[TBL] [Abstract][Full Text] [Related]
48. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract][Full Text] [Related]
49. [Efficacy of additional two cycles of rituximab administration for patients with diffuse large B-cell lymphoma in first remission].
Zhong HJ; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):756-761. PubMed ID: 27719717
[TBL] [Abstract][Full Text] [Related]
50. Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution.
Salas MQ; Mercadal S; Domingo Domenech E; Oliveira AC; Encuentra M; Climent F; Andrade Campos M; Aguilera C; Fernández de Sevilla A; Sureda A; González-Barca E
Leuk Lymphoma; 2020 Mar; 61(3):575-581. PubMed ID: 31684781
[TBL] [Abstract][Full Text] [Related]
51. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK
Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046
[TBL] [Abstract][Full Text] [Related]
52. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy.
Montes-Moreno S; Martinez N; Sanchez-Espiridión B; Díaz Uriarte R; Rodriguez ME; Saez A; Montalbán C; Gomez G; Pisano DG; García JF; Conde E; Gonzalez-Barca E; Lopez A; Mollejo M; Grande C; Martinez MA; Dunphy C; Hsi ED; Rocque GB; Chang J; Go RS; Visco C; Xu-Monette Z; Young KH; Piris MA
Blood; 2011 Jul; 118(4):1034-40. PubMed ID: 21633089
[TBL] [Abstract][Full Text] [Related]
53. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
[TBL] [Abstract][Full Text] [Related]
54. Central Nervous System International Prognostic Index Impacts Overall Survival in Diffuse Large B-cell Lymphoma Treated with R-Chop in a third Level Cancer Center from Mexico: A Survey of 642 Patients.
Solís-Armenta R; Cacho-Díaz B; Gutiérrez-Hernández O; Candelaria-Hernández M
Rev Invest Clin; 2021 Apr; 73(4):231-237. PubMed ID: 33845484
[TBL] [Abstract][Full Text] [Related]
55. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
[TBL] [Abstract][Full Text] [Related]
56. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.
Han Y; Yang J; Liu P; He X; Zhang C; Zhou S; Zhou L; Qin Y; Song Y; Sun Y; Shi Y
Oncologist; 2019 Nov; 24(11):e1251-e1261. PubMed ID: 30952824
[TBL] [Abstract][Full Text] [Related]
57. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
58. A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.
Cai J; Tian X; Ma S; Zhong L; Li W; Wang L; Guo L; Li Z; Wu Y; Zhong G; Huang H; Xia Z; Xia Y; Liu P; Su N; Fang Y; Zhang Y; Cai Q
Br J Cancer; 2021 Aug; 125(3):402-412. PubMed ID: 34012033
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of clinical and prognostic factors for primary gastric diffuse large B-cell lymphoma: Single-center experience.
Bardakci M; Esmer DD; Hafizoglu E; Karaman K; Kuzu OF; Karakas H; Gungorer B; Uncu D
J Cancer Res Ther; 2023; 19(3):778-782. PubMed ID: 37470610
[TBL] [Abstract][Full Text] [Related]
60. A promising prognostic model for predicting survival of patients with HIV-related diffuse large B-cell lymphoma in the cART era.
Chen J; Wu Y; Kang Z; Qin S; Ruan G; Zhao H; Tao X; Xie Z; Peng J
Cancer Med; 2023 Jun; 12(11):12470-12481. PubMed ID: 37081761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]